Sanofi’s dupixent approved in the US as the first-ever biologic medicine for patients with COPD
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype
At 24 months, data from the Phase 1 exPDite trial continue to show a favorable safety profile in all 12 participants in the trial’s high and low dose cohorts
The mobile unit "Breast Health Express" brings advanced medical technology directly to communities in need
Pfizer's decision is based on the totality of clinical data
This initiative aims to raise awareness about the importance of monitoring blood sugar levels before indulging in sweets
The raised capital enables Medix Biochemica to continue execution of inorganic growth initiatives
The objectives of the campaign are to raise awareness about glaucoma, its risk factors, and the importance of regular eye check-up
Stable profits, low leverage to keep credit profiles comfortable
A multi-disciplinary team of senior physicians opted to use Zidebactam/Cefepime under compassionate use
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma
Subscribe To Our Newsletter & Stay Updated